Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775

3 Apr 2019

Abstract excerpt

The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21 (HCT116 p21-/-, RPE p21-/-, and U2OS transfected with p21 siRNA) showed higher induction of the DNA damage marker γH2AX in S-phase in response to MK1775...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Molecular Biology Techniques and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30943845
DOI: 10.1080/15384101.2019.1593649

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775PMID 30943845Read ↗

Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase InhibitionSemantic proximity Read ↗

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agentsSemantic proximity Read ↗

Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damageSemantic proximity Read ↗

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant ConcentrationsSemantic proximity Read ↗

Molecular Pathways: Targeting the Protein Kinase Wee1 in CancerSemantic proximity Read ↗

Wee1 kinase as a target for cancer therapySemantic proximity Read ↗

Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.Semantic proximity Read ↗

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)Semantic proximity Read ↗

A haploid genetic screen identifies the G 1 /S regulatory machinery as a determinant of Wee1 inhibitor sensitivitySemantic proximity Read ↗

p21 and p27: roles in carcinogenesis and drug resistanceSemantic proximity Read ↗

Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging AgentsSemantic proximity Read ↗

Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.